After pumping hundreds of millions into R&D and clinical trials in development of COVID-19 vaccines, biopharma companies need contract development and manufacturing organizations (CDMOs) they can trust to handle the high-priority and high-volume product. Even more than seeing CDMOs as pure packaging and distribution partners, companies are realizing that CDMOs have the added value of being cutting-edge service providers focused on helping biopharma companies deliver exceptional customer experiences and service.
In this playbook from PCI, we explore the:
- Challenges of vaccine development and distribution
- Current and future trends impacting how vaccines are delivered and consumed
- Desirable attributes to look for in choosing the right CDMO partner